Huo Xing Cai Jing reports that on November 5, Moderna’s stock closed up approximately 13.1%, about 5.11% higher than its 52-week high set on October 21. The company is set to release its third-quarter earnings on November 6, with market attention focused on its vaccine business and progress in oncology therapy development. On the news front, the Ebola candidate vaccine mRNA-1469 has been recommended by the WHO Technical Advisory Group for advancement to Phase II/III trials, and early clinical data for the multiple myeloma candidate therapy mRNA-2808 has been selected for an oral presentation at the American Society of Hematology annual meeting. According to TradingBeats monitoring, the MRNA contract on Hyperliquid touched $268.31 this morning and was recently quoted at $257.05. Trading activity has risen accordingly. The 24-hour trading volume increased from approximately $20.48 million during the same period yesterday to $48.02 million, a rise of about 134.5%; the notional value of open interest rose from $21.29 million to $27.40 million, an increase of approximately $6.11 million, or 28.7%. The rally has put pressure on large short positions. The largest short position remains at approximately $11.58 million in MRNA shorts, with an average entry price of around $211, resulting in a current unrealized loss of about $2.086 million.
Moderna stock rises 13% on pre-earnings research hints
MarsBitShare
Moderna's stock rose 13.1% on November 5, 2026, reaching a new intraday high. On-chain data indicates growing interest ahead of its Q3 earnings report on November 6. The WHO endorsed advancing its Ebola vaccine candidate to Phase II/III trials, and early data on mRNA-2808 was selected for an oral presentation at ASH. On Hyperliquid, MRNA contracts briefly peaked at $268.31, with the current price at $257.05. On-chain analysis shows that 24-hour trading volume surged 134.5% to $48.02 million, and open interest increased 28.7% to $27.4 million. Large short positions are now incurring losses, with the largest short, valued at $11.58 million, down $2.086 million.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.
